ClinicalTrials.gg
RecruitingNCT07043335Updated Feb 18, 2026

Comparison of the Efficacy of Mesotherapy and Extracorporeal Shock Wave Therapy in Patients With Lateral Epicondylitis

An interventional study of Extracorporeal Shock Wave Therapy and Mesotherapy in Lateral Epicondylitis and Tennis Elbow, sponsored by Haydarpasa Numune Training and Research Hospital. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-02-18.

Sponsored by Haydarpasa Numune Training and Research Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as recruiting.
  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 82 studies in Tennis Elbow with a site in Turkey — 20 open to participants now, 21 under way, none of them phase 3. Tennis Elbow · Turkey.

Planned enrollment
35th of 70
50 · median 50
Started
2025
with 16 others
No phase
68 of 82
14 open now
Primary completion
2026-02
later than 6 of 20 live
Registered
49th of 82
by date
Lead sponsor
3 of 82
Haydarpasa Numune Training and Research Hospital

Among the 82 studies in Tennis Elbow with a site in Turkey, this one is the 35th largest by planned enrollment of the 70 interventional ones that give a count, is one of 17 that started in 2025, is one of 68 with no phase, reaches primary completion later than 6 of the 20 other live ones, and was the 49th registered.

Tennis Elbow

296 studies on the registry are indexed under Tennis Elbow; 63 are open to participants now.

Browse Tennis Elbow studies →

Open to participants now

20 of the 82 studies in Tennis Elbow with a site in Turkey are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 42 Tennis Elbow studies recruiting now, 8 (19%) set no upper age limit and 31 (74%) stop at 75 or younger; 1 takes children under 18; 5 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 82 studies in Tennis Elbow with a site in Turkey, or all of them as a file.
02

Study summary

The goal of this clinical trial is to investigate the efficacy of mesotherapy in patients with lateral epicondylitis and to determine whether it is as effective as extracorporeal shock wave therapy (ESWT).

Is mesotherapy an effective method in patients with lateral epicondylitis?

Researchers will compare Mesotherapy to extracorporeal shock wave therapy (ESWT) in patient with Lateral epicondylitis.

Patients will be randomly assigned to either the Mesotherapy group or the ESWT group using a closed envelope method.

  • Group 1 (Mesotherapy group): Patients will receive a total of 5 sessions of mesotherapy, with one session every 7 days.
  • Group 2 (ESWT group): Patients will receive a total of 5 sessions of Extracorporeal Shock Wave Therapy (ESWT), with one session every 7 days.

Patients will be assessed at three time points: before treatment, 30 minutes after the completion of the treatment, and 12 weeks after the completion of the treatment

Read the detailed description

This randomised-controlled single-blind prospective study was carried out at a Physical Medicine and Rehabilitation out-patient clinic. After approval by the Ethics Committee, all participants signed a written informed consent form. The research was conducted in accordance with the Helsinki Declaration.

Participants

The study will include individuals with lateral epicondylitis who are between the ages of 18 and 65 and have had elbow pain for at six weeks. Pain around the lateral epicondyle during resisted extension of wrist and fingers and tenderness over the lateral epicondyle were required for the diagnosis of lateral epicondylitis. Patients with the following exclusion criteria were not accepted into the study:

  • Receiving an interventional injection in the elbow region within the last 3 months
  • Receiving physical therapy in the last 3 months
  • Receiving regular nonsteroidal anti-inflammatory drug (NSAID) treatment in the last 2 weeks
  • History of fracture or surgery in the affected elbow region
  • Chronic inflammatory diseases
  • Acute infection
  • History of malignancy
  • Coagulation disorders
  • Pregnancy
  • Presence of a pacemaker or electronic implants
  • Cervical radiculopathy and entrapment neuropathy
  • Drug allergies
  • BMI > 35

Demographic informations were recorded. Severity of elbow pain in activity were recorded according to Visual analogue Scale (VAS). Functional impairment were evaluated with The Patient-Rated Tennis Elbow Evaluation , Short-Form-Health-Survey-12 (SF-12 )

Following clinical assessment, patients were divided into two treatment groups randomly. Mesotherapy and Extracorporeal Shock wave Therapy . Exercise and resting wrist splints were recommended for all groups.

The first group received mesotherapy: For this group, a solution containing 1 cc each of lidocaine, pentoxifylline, thiocolchicoside, and meloxicam diluted ¼ with saline will be made. A 30 gauge, 4 mm mesotherapy injector will be used for the application. The lateral epicondyle will be the site of an intradermal injection. Of that amount, 2.5 cc will be applied point-by-point at intervals of 1-2 cm, and the remaining 2.5 cc will be applied using the napage method, 0.1 cc of solution were given with each injection.

Group 2 received Extracorporeal Shock Wave Therapy will be applied to the lateral epicondyle area at 10-15 Hz frequency, 1.5-2.5 bar energy density, and 2000 pulses. Patients will receive a total of 5 sessions of Extracorporeal Shock Wave Therapy (ESWT), with one session every 7 days.

All measures were conducted at baseline, after treatment, at 12 weeks follow-ups.

03

Conditions studied

  • Lateral Epicondylitis
  • Tennis Elbow

Browse trials for

Keywords

  • elbow pain
  • mesotherapy
  • lateral epicondylitis
  • extracorporeal shock wave therapy
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria

  • Aged between 18 and 65 years
  • Pain and tenderness in the unilateral lateral epicondyle for ≥6 weeks
  • Clinically diagnosed with Lateral Epicondylitis
  • Patients without cognitive deficits who can follow verbal instructions Exclusion Criteria
  • Receiving an interventional injection in the elbow region within the last 3 months
  • Receiving physical therapy in the last 3 months
  • Receiving regular nonsteroidal anti-inflammatory drug (NSAID) treatment in the last 2 weeks
  • History of fracture or surgery in the affected elbow region
  • Chronic inflammatory diseases
  • Acute infection
  • History of
  • Coagulation disorders
  • Pregnancy
  • Presence of a pacemaker or electronic implants
  • Cervical radiculopathy and entrapment neuropathy
  • Drug allergies
  • > 35
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Active comparator
    Group 1 (Mesotherapy group)

    The intradermal mesotherapy will be applied to the painful points in the elbow using a 4 mm long, 30G needle with a point-by-point technique at a 90-degree angle. The injection volume per point will be 0.1 cc. Following this, a "nappage" technique with a 45-degree angle will be applied around the common extensor tendon.Mesotherapy solution will contain 1 cc 0.1% lidocaine, 1 cc pentoxifylline, 1 cc thiocolchicoside, 1 cc meloxicam 1⁄4 diluted with 0.9% physiological isotonic saline. Patients will receive a total of 5 sessions of mesotherapy, with one session every 7 days.

    Procedure: Mesotherapy

  • Active comparator
    Group 2 (ESWT group)

    For patients in Group 2, Extracorporeal Shock Wave Therapy will be applied to the lateral epicondyle area at 10-15 Hz frequency, 1.5-2.5 bar energy density, and 2000 pulses. Patients will receive a total of 5 sessions of Extracorporeal Shock Wave Therapy (ESWT), with one session every 7 days.

    Device: Extracorporeal Shock Wave Therapy

Interventions

  • DeviceExtracorporeal Shock Wave Therapy

    For patients in Group 2, Extracorporeal Shock Wave Therapy will be applied to the lateral epicondyle area at 10-15 Hz frequency, 1.5-2.5 bar energy density, and 2000 pulses. Patients will receive a total of 5 sessions of Extracorporeal Shock Wave Therapy (ESWT), with one session every 7 days.

  • ProcedureMesotherapy

    Intradermal mesotherapy involving lidocaine, pentoxifylline, meloxicam, and thiocolchicoside will be applied to painful elbow points using a 4 mm, 30G needle in a point-by-point technique at a 90° angle (0.1 cc per point). A nappage technique at a 45° angle will then be applied around the common extensor tendon. A total of five sessions will be administered, one every 7 days.

06

What researchers measure

Primary outcomes

  1. VAS

    Measurement of pain intensity using the Visual Analogue Scale (VAS). The VAS consists of a 10 cm line with endpoints representing 0 ("no pain") and 10 ("pain as bad as it could possibly be"). Minimum score: 0 Maximum score: 10 Higher scores indicate worse pain.

    Time frame: All measures were conducted at baseline, at the end of treatment (Week 5), at 12th weeks follow-up

  2. Patient-Rated Tennis Elbow Evaluation

    The Patient-Rated Tennis Elbow Evaluation (PRTEE) is a 15-item questionnaire designed to measure forearm pain and disability in patients with lateral epicondylitis (tennis elbow). Scores range from 0 to 100, with higher scores indicating greater pain and disability.

    Time frame: All measures were conducted at baseline, At the end of treatment (Week 5), at 12th weeks follow-ups

  3. SF-12 Health Survey

    A self-reported measure assessing health-related quality of life. Scores range from 0 to 100, with higher scores indicating better health status.

    Time frame: All measures were conducted at baseline,At the end of treatment (Week 5) , 12th weeks follow-ups

Secondary outcomes

  1. Algometer Measurement of Pressure-Pain Threshold

    Measurement of pressure-pain threshold using an algometer device. Values are measured in kilopascals (kPa). Higher values indicate higher pain tolerance.

    Time frame: All measures were conducted at baseline,At the end of treatment (Week 5) , at 12th weeks follow-ups.

  2. Hand Dynamometer for Grip Strength

    Measurement of grip strength using a hand dynamometer. Values are measured in kilograms (kg). Higher values indicate stronger grip strength.

    Time frame: All measures were conducted at baseline,At the end of treatment (Week 5) , at 12th weeks follow-ups.

07

Study locations

1 of 1 sites recruiting
  • Health Science University Haydarpasa Numune Research and Training Hospital, Istanbul, Uskudar 34668
    Istanbul, Turkey (Türkiye)
    Recruiting
08

References and documents

Publications

  • Mammucari M, Gatti A, Maggiori S, Sabato AF. Role of mesotherapy in musculoskeletal pain: opinions from the italian society of mesotherapy. Evid Based Complement Alternat Med. 2012;2012:436959. doi: 10.1155/2012/436959. Epub 2012 May 13. PubMed 22654954 ↗

Related links

Individual participant data

Plan to share: Yes — all IPD

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: starting 6 months after publication

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Feb 2026, 7 months after the start.

Of 152 non-industry interventional studies with no phase under Tennis Elbow, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 24. This study's planned 7 months is below that.

Counting every sponsor, half of 154 studies reached it within 8 months; a quarter within 5 and three quarters within 22.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2024
First posted
Jun 29, 2025
StartActual
Jul 1, 2025
Primary completionEst.
Feb 15, 2026
CompletionEst.
Feb 20, 2026
Last update
Feb 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07043335
Lead sponsor
Haydarpasa Numune Training and Research Hospital
Responsible party
Berna Gunay, MD (Specialist Physician, Haydarpasa Numune Training and Research Hospital) — Principal investigator
First posted
Jun 29, 2025
Start date
Jul 1, 2025
Primary completion
Feb 15, 2026 (estimated)
Completion
Feb 20, 2026 (estimated)
Last update
Feb 18, 2026

Study contacts

Berna Gunay, Medical doctor
Contact
bernagunay@yahoo.com
+905354133047

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion